万邦德：阿尔茨海默病新药临床入组完成百例

Core Viewpoint - Wanbangde's subsidiary has developed a new drug, "Shisuanjianma Controlled-release Tablets," for treating mild to moderate Alzheimer's disease, which has completed the enrollment of 100 subjects in its critical II/III phase clinical trial [1] Group 1: Drug Development - The new drug is characterized by a dual-phase controlled-release technology that stabilizes the drug release curve, prolongs the release time in the body, and aims to reduce adverse reactions while enhancing dosage safety [1] - The clinical trial is led by the Capital Medical University Xuanwu Hospital, with Professor Jia Jianping, a leading expert in the field of neurology, overseeing the project in collaboration with over 50 top research centers nationwide [1] Group 2: Research and Collaboration - The drug has been selected for the National Science and Technology Major Project for Innovative Drug Development, highlighting its significance in utilizing local resources, as its active ingredient is derived from the traditional Chinese medicinal plant, Qianshengtang (Sarcandra glabra) [1] - Wanbangde is steadily advancing the subject enrollment process and will continue close collaboration with Xuanwu Hospital and other research institutions to further validate the drug's safety and efficacy, providing critical data support for future market application [1]